These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 10319395)

  • 21. Factors leading patients to discontinue multiple sclerosis therapies.
    Daugherty KK; Butler JS; Mattingly M; Ryan M
    J Am Pharm Assoc (2003); 2005; 45(3):371-5. PubMed ID: 15991759
    [TBL] [Abstract][Full Text] [Related]  

  • 22. To treat, or not to treat: the therapeutic dilemma of idiopathic monosymptomatic demyelinating syndromes.
    Frohman EM; Racke M; van Den Noort S
    Arch Neurol; 2000 Jul; 57(7):930-2. PubMed ID: 10891973
    [No Abstract]   [Full Text] [Related]  

  • 23. [Interferon beta and copolymer-1: mechanism of action and clinical effects in multiple sclerosis].
    Losy J
    Neurol Neurochir Pol; 2000; 34(3 Suppl):63-9. PubMed ID: 10983302
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Multiple sclerosis (MS), an inflammatory or degenerative disease?].
    Confavreux C; Vukusic S
    Presse Med; 2004 Feb; 33(3):151-2. PubMed ID: 15029024
    [No Abstract]   [Full Text] [Related]  

  • 25. Guidance on new therapies in multiple sclerosis patients.
    Gonsette RE
    Lancet; 1996 Jul; 348(9020):136. PubMed ID: 8676708
    [No Abstract]   [Full Text] [Related]  

  • 26. Comment on Shuhaibar et al.: Favourable effect of immunomodulator therapy on bone mineral density in multiple sclerosis.
    Kampman MT; Steffensen LH
    Ir J Med Sci; 2009 Jun; 178(2):235-6; author reply 237-8. PubMed ID: 19184608
    [No Abstract]   [Full Text] [Related]  

  • 27. Disease-modifying drugs for multiple sclerosis: a rapid and systematic review.
    Clegg A; Bryant J; Milne R
    Health Technol Assess; 2000; 4(9):i-iv, 1-101. PubMed ID: 10944743
    [No Abstract]   [Full Text] [Related]  

  • 28. The effect of glatiramer acetate treatment on pre-existing headaches in patients with MS.
    Pöllmann W; Erasmus LP; Feneberg W; Straube A
    Neurology; 2006 Jan; 66(2):275-7. PubMed ID: 16434675
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of multiple sclerosis and related disorders: what's new in the past 2 years?
    Noseworthy JH
    Clin Neuropharmacol; 2003; 26(1):28-37. PubMed ID: 12567162
    [No Abstract]   [Full Text] [Related]  

  • 30. Glatiramer acetate versus interferon beta-1a for subcutaneous administration: comparison of outcomes among multiple sclerosis patients.
    Castelli-Haley J; Oleen-Burkey M; Lage MJ; Johnson KP
    Adv Ther; 2008 Jul; 25(7):658-73. PubMed ID: 18641926
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multiple sclerosis treatment 2001.
    Rolak LA
    Neurol Clin; 2001 Feb; 19(1):107-18. PubMed ID: 11471759
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience.
    Ghezzi A; Amato MP; Annovazzi P; Capobianco M; Gallo P; La Mantia L; Marrosu MG; Martinelli V; Milani N; Moiola L; Patti F; Pozzilli C; Trojano M; Zaffaroni M; Comi G;
    Neurol Sci; 2009 Jun; 30(3):193-9. PubMed ID: 19387545
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Logistics and description of treatment technology (the protocol for using disease modifying drugs--DMD)].
    Federal service on surveillance in healthcare and social development (Roszdravnadzor)
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(2 Pt 2):93-8. PubMed ID: 21916163
    [No Abstract]   [Full Text] [Related]  

  • 34. Putative mechanisms of action of statins in multiple sclerosis--comparison to interferon-beta and glatiramer acetate.
    Neuhaus O; Stüve O; Archelos JJ; Hartung HP
    J Neurol Sci; 2005 Jun; 233(1-2):173-7. PubMed ID: 15949504
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis.
    Prosser LA; Kuntz KM; Bar-Or A; Weinstein MC
    Value Health; 2004; 7(5):554-68. PubMed ID: 15367251
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Editorial: the pitfalls of combination therapy.
    Vermersch P
    Int MS J; 2006 Nov; 13(3):75-6. PubMed ID: 17101074
    [No Abstract]   [Full Text] [Related]  

  • 37. New acute and chronic black holes in patients with multiple sclerosis randomised to interferon beta-1b or glatiramer acetate.
    Cadavid D; Cheriyan J; Skurnick J; Lincoln JA; Wolansky LJ; Cook SD
    J Neurol Neurosurg Psychiatry; 2009 Dec; 80(12):1337-43. PubMed ID: 19687024
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS.
    Tremlett HL; Oger J
    Neurology; 2003 Aug; 61(4):551-4. PubMed ID: 12939437
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multiple sclerosis: monotherapy rules.
    Hauser SL; Josephson SA; Johnston SC
    Ann Neurol; 2013 Mar; 73(3):A5-6. PubMed ID: 23596013
    [No Abstract]   [Full Text] [Related]  

  • 40. [The technology of treatment of multiple sclerosis with long-term immunomodulating drugs (disease modifying drugs--DMD)--beta-interferons and glatiramer-acetate].
    Federal service on surveillance in healthcare and social development (Roszdravnadzor)
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(2 Pt 2):86-92. PubMed ID: 21916162
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.